Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Japan (P8-12.006)
The primary objective was to compare the efficacy of rimegepant (RIM) 75 mg with placebo (PBO) for the acute treatment of migraine in participants living in Japan. A secondary objective was to compare the efficacy of RIM 25 mg with PBO to assess dose response.
Authors
- Fumihiko Sakai (ORCID: https://orcid.org/0000-0001-9385-7991)
- Akio Arakawa
- Takao Takeshima (ORCID: https://orcid.org/0000-0003-2678-6956)
- Tomofumi Ishikawa (ORCID: https://orcid.org/0000-0002-0901-368X)
- Koichi Ikeda (ORCID: https://orcid.org/0009-0002-6562-7472)
- Robert Croop (ORCID: https://orcid.org/0009-0004-0151-1192)
- Terence Fullerton
- Alexandra Thiry
- Hiroki Yoshimatsu
- Yasuhiko Matsumori (ORCID: https://orcid.org/0000-0001-5852-0146)
- Yuko Hoshino (ORCID: https://orcid.org/0000-0002-3501-0810)
- Masako Kudo
Institutions
- Iwate Medical University (JP)
- Pfizer (United States) (US)
- Tominaga hospital (JP)
- Biohaven Pharmaceuticals (United States) (US)
- Shibuya (Japan) (JP)
- Pfizer (Japan) (JP)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210351
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00